Allarity Therapeutics (ALLR) Total Non-Current Liabilities (2020 - 2025)

Allarity Therapeutics (ALLR) has 6 years of Total Non-Current Liabilities data on file, last reported at $8.4 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 22.22% year-over-year to $8.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.4 million (down 22.22% YoY) and the FY2025 annual result came in at $8.4 million, down 22.22% from the prior year.
• Total Non-Current Liabilities slipped to $8.4 million in Q4 2025, from $8.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $30.8 million in Q4 2021 to a low of $432000.0 in Q1 2024.
• A 5-year average of $9.7 million and a median of $9.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 89.83% — and 2025, when it soared 2460.42%.
• Tracing ALLR's Total Non-Current Liabilities over 5 years: stood at $30.8 million in 2021, then tumbled by 60.17% to $12.3 million in 2022, then advanced by 19.25% to $14.6 million in 2023, then retreated by 25.83% to $10.8 million in 2024, then slipped by 22.22% to $8.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $8.4 million (Q4 2025), $8.8 million (Q3 2025), and $9.0 million (Q2 2025), per Business Quant data.